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Alzheimer’s disease (AD) is the most common neurodegenerative disease that causes dementia in the elderly. Patients with AD
suffer a gradual deterioration of memory and other cognitive functions, which eventually leads to a complete incapacity and death.
A complicated array of molecular events has been implicated in the pathogenesis of AD. The major pathological characteristics
of AD brains are the presence of senile plaques, neurofibrillary tangles, and neuronal loss. Growing evidence has demonstrated
that oxidative stress is an important factor contributing to the initiation and progression of AD. However, the mechanisms that
lead to the disruption of redox balance and the sources of free radicals remain elusive. The excessive reactive oxygen species may
be generated from mechanisms such as mitochondria dysfunction and/or aberrant accumulation of transition metals, while the
abnormal accumulation of Abeta and tau proteins appears to promote the redox imbalance. The resulted oxidative stress has been
implicated in Abeta- or tau-induced neurotoxicity. In addition, evidence has suggested that oxidative stress may augment the
production and aggregation of Abeta and facilitate the phosphorylation and polymerization of tau, thus forming a vicious cycle
that promotes the initiation and progression of AD.
1. Introduction
Alzheimer’s disease (AD) is the most common neurodegen-
erative disease that causes dementia in the elderly. It is char-
acterized by the gradual deterioration of memory and other
cognitive functions, which eventually leads to a complete
incapacity and death of the patients within 3 to 9 years after
diagnosis[1].Increasingageisamajorriskfactorforsporadic
formsofAD.Astheelderlypopulationoftheworldcontinues
to increase, the prevalence of AD has increased remarkably
w o r l d w i d e ,a n dA Dh a sb e c o m eo n eo ft h el e a d i n gc a u s e s
of disability and death among the elderly [2–5]. Despite the
tremendous progress that has been made in AD research in
the past few decades, the exact cause and pathogenesis of
AD are not completely understood, and currently, there is no
effective treatment for the disease.
The major pathological characteristics of AD brains are
thepresenceofsenileplaques,neurofibrillarytangles(NFTs),
and neuronal loss [1, 6]. Senile plaques are mainly composed
of beta-amyloid peptide (Abeta) that is produced from
proteolyticcleavageofthetransmembraneamyloidprecursor
protein (APP). NFTs are formed by arrays of paired helical
filaments (PHFs) structures, which contain mainly self-
aggregated hyperphosphorylated tau, a multifunctional pro-
tein involved in microtubule assembly and stabilization [6].
Accumulatingevidencehasshownthatthepresenceofexten-
sive oxidative stress is a characteristic of AD brains in addi-
t i o nt ot h ee s t a b l i s h e dp a t h o l o g yo fs e n i l ep l a q u e sa n dN F T
[7]. It has been demonstrated that the levels of protein car-
bonyls and 3-nitrotyrosine, which are resulted from protein
oxidation, and markers of oxidative damage to DNA and
RNA, such as 8-hydroxydeoxyguanosine (8-OHdG) and 8-
hydroxyguanosine, are elevated in AD brains [8–12]. Prod-
ucts of lipid peroxidation, such as malondialdehyde (MDA),
4-hydroxynonenal, and F2-isoprostanes, are also increased
in multiple brain regions and cerebrospinal fluid (CSF) of
patients with AD or mild cognitive impairment (MCI) [13–
17] .I na d d i t i o nt ot h ea c c u m u l a t i o no ff r e er a d i c a ld a m a g e ,
alterations in the activities or expression of antioxidant en-
zymessuchassuperoxidedismutase(SOD)andcatalasehave
been observed in both central nervous system and periph-
eral tissues of AD patients [17–20]. Moreover, in AD and
MCI brains, the increased oxidative damage to lipids and
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enzyme activities are more localized to the synapses and cor-
relate with the severity of the disease, suggesting an involve-
ment of oxidative stress in AD-related synaptic loss [21].
Importantly, many of the previously mentioned studies show
elevations of oxidative stress in MCI, which is proposed as
an intermediate state between normal aging and dementia,
indicating that the oxidative stress damage in AD may occur
preceding the onset of the disease. These results suggest that
oxidative stress may be one of the earliest alterations that
occur during the initiation and development of AD.
While oxidative stress has emerged as one of the impor-
tant factors in AD pathogenesis, the mechanisms by which
t h er e d o xb a l a n c ei sa l t e r e da n dt h es o u r c e so ff r e er a d i c a l s
remain elusive. The present paper reviews the involvement
of abnormal accumulation of Abeta and tau proteins in the
induction of redox imbalance and the generation of free rad-
icals through mechanisms such as mitochondria dysfunction
and/ortransitionmetalhomeostasisimbalanceanddiscusses
the mechanisms by which oxidative stress promotes Abeta-
and tau-mediated neurotoxicity.
2. Oxidative Stress and Abeta-Induced Toxicity
Abeta is produced via sequential proteolytic cleavages of
APP by two membrane-bound proteases, beta-secretase, also
known as beta-site APP cleaving enzyme 1 (BACE1), and
gamma-secretase, a multiprotein complex consisting of pre-
senilin (PS), nicastrin (NCT), anterior pharynx-defective 1
(APH-1),andpresenilinenhancerprotein2(PEN-2)[1,6,22].
BACE1 cleaves APP at the N-terminal end, producing a
99 amino acid APP C-terminal fragment, which is further
cleaved within the transmembrane domain by gamma-
secretase, resulting in the release of Abeta peptides [1, 6, 23].
Severalpeptidesofvaryinglengthscanbegeneratedfromthe
cleavages by beta- and gamma-secretases; among them, the
42-amino acid form of Abeta (Abeta42) is more toxic than
the more abundantly produced 40-amino acid form of Abeta
(Abeta40), possibly because of its faster self-aggregation into
oligomers[1,23,24].Infact,multiplelinesofevidencesuggest
that soluble Abeta oligomers are the most neurotoxic, whose
levels correlate with the severity of the cognitive decline in
AD [23, 24]. Cleavage of APP by a third enzyme, alpha-
secretase, precludes the formation of toxic Abeta peptides
[25]. Increased production and/or decreased clearance of
Abeta peptides leads to the accumulation of Abeta, which
stimulates diverse cell signaling pathways, eventually result-
ing in synaptic degeneration, neuronal loss and decline in
cognitive function [6, 23, 24, 26–28].
A great deal of research has implicated oxidative stress in
Abeta-inducedneurotoxicity[29].In vitro experimentsusing
cell models showed that Abeta treatment could increase the
levels of hydrogen peroxide and lipid peroxides [30]. Con-
sistently, in various AD transgenic mouse models carrying
mutants of APP and PS-1, increased hydrogen peroxide and
nitric oxide production as well as elevated oxidative modifi-
cations of proteins and lipids were correlated with the age-
associated Abeta accumulation, confirming that Abeta pro-
motes oxidative stress [31–35]. In hippocampal neuronal cell
cultures, the induction of reactive oxygen species (ROS) by
solubleAbetaoligomersrequiredtheactivationofN-methyl-
D-aspartate (NMDA) receptor and was associated with a
r a p i di n c r e a s ei nn e u r o n a lc a l c i u ml e v e l s ,s u g g e s t i n gap o s -
sible role of soluble Abeta oligomers as proximalneurotoxins
andtheinvolvementofoxidativestressinthesynapticimpair-
ment and neuronal loss induced by soluble Abeta oligomers
[36]. Consistently, it has been demonstrated in AD cell and
animal models that natural antioxidants, such as EGb 761,
curcumin,andgreenteacatechins,canexertneuroprotective
functions by attenuating Abeta-induced ROS generation and
neuronal apoptosis [37–40].
In addition to mediating Abeta-induced cytotoxity,
numerous studies have suggested that oxidative stress pro-
motes the production of Abeta. It was demonstrated that
defects in antioxidant defense system caused elevated oxida-
tive stress and significantly increased Abeta deposition in
transgenic mice overexpressing APP mutant [41, 42], while
dietary antioxidants such as curcumin lowered the elevation
of oxidized proteins and decreased brain Abeta levels and
Abeta plaque burden [43]. Moreover, the increased Abeta
deposition and its associated earlier onset and more severe
cognitive dysfunction induced by the defect in antioxidant
defense system could be ameliorated by antioxidant supple-
mentation [42]. In line with these findings, overexpression
of manganese superoxide dismutase (MnSOD) in Tg19959
transgenic mice overexpressing APP mutant decreased pro-
teinoxidationandincreasedantioxidantdefensecapabilityin
brains while reducing Abeta plaque burden and restoring the
memory deficit [44]. Furthermore, deletion of cytoplasmic
copper/zinc superoxide dismutase (Cu-Zn-SOD, SOD1) in
Tg2576 APP-overexpressing AD mouse model was found to
increase Abeta oligomerization while accelerating the loss of
spatial learning and memory as compared with control AD
mice, suggesting a possible role of oxidative damage in Abeta
oligomerization [45]. These results suggest that the enhance-
ment of Abeta production/plaque formation as well as Abeta
oligomerization by oxidative stress is important for the
initiation and development of AD.
Studies on how oxidative stress enhances Abeta produc-
tion have revealed that oxidative stress decreases the activity
of alpha-secretase while promoting the expression and acti-
vationofbeta-andgamma-secretase,enzymescriticalforthe
generation of Abeta from APP [46–50]. The induction of
BACE1 and PS1 expression and the activation of gamma-
secretase by oxidative stress were found to be dependent on
the activation of c-Jun N-terminal kinase (JNK) pathway, a
major cell signaling cascade that is stimulated by oxidative
stress[51,52].Infact,thepromoterand5
򸀠 untranslatedregion
of BACE gene contain binding sites for multiple transcrip-
tion factors including the redox-sensitive activator protein
(AP1) and nuclear factor (NF)-kappa B, activation of which
by oxidative stress may in turn enhance BACE expression
[53]. In AD brains, both the activation of JNK signaling
cascade [54–56] and the elevation of BACE1 and PS1 expres-
sion/activity have been detected [57–59]; thus, it is possible
that the increased oxidative stress in AD brains may initiate
the activation of a cascade of redox-sensitive cell signal
pathways including JNK, which promotes the expression of
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Abetaandthedeteriorationofcognitivefunction.AsJNKhas
also been implicated in Abeta-induced neuronal apoptosis
[60], oxidative stress may enhance Abeta production as well
as mediate Abeta-induced neurotoxicity through the activa-
tion of redox-sensitive signaling pathways such as JNK.
Alternatively, the augmentation of Abeta production by
oxidative stress may be a compensatory reaction to oxidative
stress.Itwasfoundthatneuronaloxidativedamagewasmore
pronounced in AD subjects with lesser amounts of Abeta
deposition or in AD subjects with a shorter disease duration
[61, 62], and there was an inverse relationship between the
levels of neuronal oxidative damage to nucleic acids and the
amounts of intraneuronal Abeta42 in the hippocampus and
the subiculum of AD brains [63]. These unexpected observa-
t i o n sh a v el e dt ot h eh y p o t h e s i st h a tA b e t am a yp o t e n t i a l l y
play a protective role against neuronal oxidative stress [64].
Indeed, evidence has suggested that picomolar or low
nanomolar levels of Abeta can be neurotrophic or neuropro-
tective [65, 66]. Physiological concentrations of Abeta were
shown to efficiently inhibit autooxidation of lipoproteins in
CSF and plasma [67] and markedly increase hippocampal
long-term potentiation [68], whereas the high nanomolar
concentrations of Abeta caused the well-established toxic
effects. In addition, it appeared that the dualistic effects
of Abeta depended on the aggregation state of Abeta and
were Abeta size-form specific [66, 69]. Taken together, low
levels of Abeta may have a role in the normal function of
neuronal cells and could beneficially influence the cellular
redox status, while the abnormal accumulation and aggrega-
tion of specific forms of Abeta, which can be enhanced by
oxidative stress, may impair neuronal function and further
exacerbate neuronal oxidative damage, contributing to the
pathological development of AD. A better understanding of
thepathologicalaswellasthephysiologicalroleofAbetamay
lead to more effective strategies for AD interventions.
3. Mitochondria Dysfunction and Oxidative
Stress in AD
Mitochondria are unique organelles that are pivotal for a
variety of cellular functions including ATP synthesis, cal-
cium homeostasis, and cell survival and death. Meanwhile,
mitochondrial respiratory chain is a major site of ROS
p r o d u c t i o ni nt h ec e l l ,a n dm i t o c h o n d r i aa r ep a r t i c u l a r l y
vulnerable to oxidative stress [70, 71]. Extensive studies have
demonstratedthatmitochondriadysfunctionisanimportant
factorinvolvedinthepathogenesisofAD.Anumberofmito-
chondrial and metabolic abnormalities have been identified
inthehippocampalneuronsofADcomparedtoage-matched
controls[72–74].MorphometricanalysisofbiopsiesfromAD
brains showed a significant reduction of mitochondria, while
the mitochondrial DNA and protein were increased in the
cytoplasm and in the vacuoles associated with lipofuscin, a
lysosome suggested as the site of mitochondrial degradation
by autophagy [72, 73]. These mitochondrial abnormalities
w e r ef o u n da c c o m p a n i e db yo x i d a t i v ed a m a g em a r k e db y
8-hydroxyguanosine and nitrotyrosine, indicating that the
mitochondria were damaged during the progression of AD
[72]. In line with this, a significant decrease of mitochondrial
cytochrome oxidase (complex IV) activity in the cortical
regionsofADbrainswasreported[74].Deficiencyinthiskey
electron transport enzyme could lead to the increase in ROS
production and reduction in energy stores, eventually con-
tributing to the neurodegenerative process [74].
Evidence suggests that Abeta may directly disrupt mito-
chondria function and contribute to the deficiency of energy
metabolism and neuronal death seen in AD. It was found
t h a tA b e t aw a sl o c a l i z e dt om i t o c h o n d r i ai nb r a i n so fA D
patientsandtransgenicmiceaswellasinneuroblastomacells
stably expressing human mutant APP [34, 75]. The presence
of Abeta in mitochondria was associated with impaired
mitochondrialmetabolismandincreasedmitochondrialROS
production [34, 75] .I nf a c t ,i ni s o l a t e dm i t o c h o n d r i a ,A b e t a
treatment could cause oxidative injury to mitochondrial
membrane, disrupt lipid polarity and protein mobility and
inhibit key enzymes of the mitochondria respiratory chain,
leading to increased mitochondrial membrane permeability
andcytochromecrelease[76,77].MnSOD,aprimaryantiox-
idant enzyme protecting mitochondria against superoxide,
was found to be a target of nitration and inactivation in a
double homozygous knock-in mouse model expressing APP
and PS-1 mutants [78]. The decreased activity of antioxidant
defense enzymes such as MnSOD may further increase ROS
levels and compromise mitochondria function, contributing
to the loss of mitochondrial membrane potential and even-
tually caspase activation and apoptosis [78]. Abeta has also
been shown to alter other cellular protective mechanisms
against oxidative damage to mitochondria. Uncoupling pro-
teins (UCPs) are a family of mitochondrial anion carrier
proteins that are located on the inner mitochondrial mem-
brane with diverse physiological functions [79]. It has been
demonstrated that UCP2 and UCP3 can be activated by ROS
or products of lipid peroxidation to diminish proton motive
force and reduce mitochondrial membrane potential and
ATP production, causing mitochondria uncoupling and de-
creaseofROSgenerationfrommitochondria[80]. Therefore,
the expression and activation of UCPs are considered to be
a protective mechanism in response to oxidative stress. This
protective mechanism appears dysfunctional in AD brains
where the expression of UCP2, 4, and 5 is significantly de-
creased[81].InSH-SY5Yneuroblastomacellsoverexpressing
A P Po rA P Pm u t a n t ,i tw a sf o u n dt h a tt h eu p r e g u l a t i o no f
UCP2 and UCP4 protein levels in response to the exposure
of superoxide was abrogated; although the mechanisms are
unclear, it suggests that Abeta accumulation may lead to
irreversible cellular alterations that render the cell more
susceptible to oxidative stress [82]. Moreover, the UCP2- and
UCP4-dependent upregulation of mitochondrial free cal-
cium in response to superoxide treatment was found to be
diminishedincellsoverexpressingAPPorAPPmutant,indi-
cating that the Abeta accumulation may be associated with
a dysfunction of mitochondria as a reserve pool of intracel-
lular calcium that leads to an increased cell sensitivity to the
loss of calcium homeostasis [82].
It is noted that the mitochondria-associated Abeta along
with the increase in hydrogen peroxide and decrease in
cytochromeoxidaseactivitywasdetectedpriortotheappear-
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occurs earlier in the pathogenesis of AD. Therefore, early
mitochondrially targeted therapeutic interventions may be
effectiveindelayingtheonsetandprogressionofAD[34,75].
4. Metal Homeostasis and Oxidative Stress
in AD
Transition metals such as copper (Cu), zinc (Zn), and iron
(Fe) play important catalytic roles in many enzymes and are
essential for a broad range of biological processes in human
body including brain functions. Both Cu and Zn have been
shown to participate in regulating synaptic function. Follow-
ing NMDA receptor activation, Cu is released from the neu-
ron and regulates neuronal activation by functionally block-
ing NMDA receptors and limiting calcium entry into the
cell [83]. Zn also has a neuromodulatory role; it is released
from presynaptic nerve terminals into the synaptic cleft
upon neuronal activation and has been shown to inhibit
excitatory NMDA receptors [84]. Fe is crucial for neuronal
processes such as myelination, synaptogenesis, and synaptic
plasticity (SP). It is well documented that deficiency of Fe
can induce a series of neurochemical alterations that may
eventually lead to cognitive deficits [85]. While these tran-
sition metals play essential roles in neural functions, their
levels and transport are strictly regulated, as aberrant metal
homeostasiscanresultinneurotoxicfree-radicalproduction.
Forexample,excessFeorCucandirectlyinteractwithoxygen
to produce superoxide ion, hydrogen peroxide, and hydroxyl
radical, which may lead to oxidative stress and a cascade of
biochemical alterations that eventually cause neuronal cell
death[86].Infact,growingevidencehasshownthatthereisa
close relationship between the disruption of metal home-
ostasis and AD [86]. Abnormal levels of Cu, Zn, and Fe
havebeenobservedinADhippocampusandamygdala,areas
showing severe histopathologic alterations [87]. Moreover,
thesetransitionmetalshavebeendetectedwithintheamyloid
d e p o s i t si nA Dp a t i e n t sa sw e l la st r a n s g e n i cm o u s em o d e l s
[88–90]. These data suggest that the aberrant accumulation
of transition metals may be inextricably linked with Abeta
pathology in AD; however, the precise cause and the nature
of the involvement of brain metal dyshomeostasis in AD are
still largely unknown.
The presence of transition metals within the amyloid
deposits in AD patients indicates that transition metals may
directly interact with Abeta [88–90]. Indeed, both Cu
2+ and
Zn
2+ canbindtoAbetamonomersviathreehistidineresidues
(His
6,H i s
13,a n dH i s
14) and a tyrosine residue (Tyr
10), caus-
ing conformational changes of the peptide that promote its
aggregation [91, 92]. Consistently, in vitro data showed that
Cu and Zn rapidly induced the aggregation of soluble Abeta
peptides [93, 94]. Therefore, the disturbance of metal home-
ostasis and the abnormal interactions of Abeta with metal
ions may be directly involved in the process of Abeta depo-
sition in AD brains [93–96]. In addition, the aberrant inter-
action between transition metals and Abeta may be a source
of ROS generation. Abeta binds Cu
2+ with high affinity,
forming a cuproenzyme-like complex [91]. Electrons can be
transferred from Abeta to Cu, reducing Cu
2+ to Cu
+ and
forming positively charged Abeta radical (Abeta
+∙)[ 97]. Cu
+
then donates two electrons to oxygen, generating H2O2 [97,
98] ,s e t t i n gu pc o n d i t i o n st of u r t h e rp r o d u c eh y d r o x y lr a d i -
cals(Fenton-typereaction)[99,100].Afterelectrondonation
to O2, the radicalized ⋅Cu
2+ complex may be restored to
Abeta⋅Cu
2+ by electron transfer from biological reducing
agents such as cholesterol, catecholamines, and vitamin C
[97]. The efficiency for generation of H2O2 is greater for
Abeta42thanAbeta40,correlatingwiththeircytotoxicactiv-
ity [98, 99]. Similar to copper-Abeta interaction, binding of
FetoAbetaresultsinreductionofFe
3+ toFe
2+ andthegener-
ation of H2O2 [101]. These data suggest that ROS generated
from the interaction of transition metals with Abeta are
key contributors to the oxidative stress in Abeta-mediated
neurotoxicity and AD pathogenesis.
Additionally, there is a close association between Fe/Cu
homeostasis and the production and processing of APP. In
SH-SY5Y cells overexpressing the Swedish mutant form of
h u m a nA P P( A P P s w ) ,F et r e a t m e n ti n d u c e dt h er e l e a s eo f
Abeta42 [102, 103]. Moreover, an iron-responsive element
(IRE-TypeII)wasidentifiedwithinthe5
򸀠-untranslatedregion
(5
򸀠-UTR) of APP transcript, which was selectively downreg-
ulated in response to intracellular Fe chelation; thus, in addi-
tion to promotion of Abeta generation from APP, increases
in Fe levels may lead to upregulation of APP protein trans-
lation through binding of Fe regulatory proteins to the APP
IRE [104]. On the contrary, Cu treatment was shown to pro-
motethenonamyloidogenicpathwayofAPPanddecreasethe
release of Abeta [105] .Th i sm a yb er e l a t e dt ot h efi n d i n gt h a t
CuisabnormallydistributedinADbrain,withaccumulation
of Cu in amyloid plaques but a deficiency of Cu in neighbor-
ing cells [87, 88].
Studies have shown that metal transporters such as
Zn transporters and divalent metal transporter 1 (DMT1)
a r ei n c r e a s e di nt h ec o r t e xa n dh i p p o c a m p u so fA P P / P S 1
transgenic mice; and similar to transition metals, these metal
transporters are colocalized with Abeta in senile plaques in
thecortexofADbrains[103,106,107].Thisleadstothespecu-
lationthatmetaltransportersmayplayimportantrolesinthe
aberrantmetalhomeostasisinAD.DMT1,alsoknownasnat-
uralresistance-associatedmacrophageprotein2(Nramp2)or
divalent cation transporter 1 (DCT1), is a newly discovered
proton-coupled metal-ion transport protein responsible for
t h eu p t a k eo fab r o a dr a n g eo fd i v a l e n tm e t a li o n s ,i n c l u d i n g
Fe, Cu, and Zn [108]. In APPsw cells, where a significant
increase in DMT1 levels was found when compared to the
control cells [103], it was observed that the intracellular Fe
was significantly elevated along with the increased oxidative
stress and cell toxicity [102, 103]. Silencing of endogenous
DMT1 by RNA interference (RNAi) decreased the protein
levels of DMT1 and also reduced bivalent ion influx into
the cells, suggesting that the elevation of DMT1 might be
involved in the disruption of Fe homeostasis seen in APPsw
cells [102, 103].
APP, which has a Cu binding site at N-terminal cysteine-
rich region [109], generates free radicals when interacting
w i t hC u .I na d d i t i o n ,A P Ph a sb e e ns h o w nt om o d u l a t eC u
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mice caused a significant reduction in Cu levels [110]. In
APP knockout mice, Cu levels were significantly elevated in
cerebral cortex, a region of the brain particularly involved
in AD [111, 112]. This leads to the speculation that the
secreted APP and/or Abeta may promote the efflux of Cu or
prevent its uptake, thus reducing its levels [110]. In SH-SY5Y
cells, it was found that endogenous APP had a partial
colocalization with the Golgi marker GM130, while the
elevation of cellular Cu levels promoted the exit of APP from
the Golgi to a wider distribution throughout the cytoplasm
and to the plasma membrane [113]. It was suggested that the
increase in cell surface APP was resulted from a concomitant
increase in exocytosis and reduction in endocytosis [113].
The copper-responsive trafficking of APP is therefore con-
sistent with a role for APP in Cu efflux pathways [111, 113].
These observations suggest that there is an interdependent
relationship between APP metabolism and Cu homeostasis,
p e r t u r b a t i o n so fe i t h e rm a yc a u s ea l t e r a t i o no ft h eo t h e r ,
eventually promoting the accumulation of Abeta and the
generation of free radicals [112].
As aberrant metal homeostasis plays an important role
in several important aspects of AD pathogenesis including
the production and aggregation of Abeta and the oxidative
stress mediated by Abeta, AD therapy-targeted metal-Abeta
interaction is rapidly emerging as a promising therapeutic
option. Various metal chelating compounds have been tested
for their efficacy [114]. One of these compounds, clioquinol
(CQ), an orally bioavailable Cu/Zn chelator, was shown to
block Abeta-induced production of H2O2 and Zn
2+/Cu
2+-
induced precipitation of synthetic Abeta in vitro and signifi-
cantlyreducethelevelofAbetadepositioninbrainsofTg2576
transgenic mice [96, 115]. In a randomized, double-blind,
placebo-controlled clinical intervention using clioquinol in
patients with moderately severe AD, CQ treatment lowered
plasma Abeta42 levels and slowed cognitive impairment
in the more severely affected patients (baseline cognitive
subscalescoreoftheADAssessmentScale,≥25)duringa36-
week period [116].
Since the generation of ROS is an important factor in
AD pathogenesis promoted by the aberrant accumulation of
transition metals, natural antioxidants may have protective
effects against AD pathogenesis induced by disruption of
metal homeostasis [117]. As expected, treatment with antiox-
idantnicotineattenuatedthecopper-facilitatedneurotoxicity
induced by Abeta in APPsw cells while decreasing the intra-
cellular Cu concentration [90]. Consistently, nicotine treat-
ment significantly lowered the Cu and Zn concentrations in
senile plaques and a subfield of the hippocampus CA1 region
in the brains of APPV717I (London mutant form of APP)
transgenic mice, and these effects were found to be inde-
pendent of the activation of nicotinic acetylcholine receptors
[90]. These results suggest that antioxidants such as nicotine
m a ya l s oh a v ear o l ei nr e g u l a t i n gm e t a lh o m e o s t a s i s .
5. Oxidative Stress and Tau Pathology
Hyperphosphorylated tau protein is the major component
of NFT, another hallmark of AD pathology that correlates
withneurodegenerationandcognitivedecline[6]. Abnormal
hyperphosphorylationoftauimpairsitsbindingwithtubulin
and its capacity to promote microtubule assembly, resulting
in its self-aggregation into filaments [118] .An u m b e ro fp r o -
tein kinases and protein phosphatases have been implicated
in the abnormal phosphorylation of tau including glyco-
gen synthase kinase-3 beta (GSK-3 beta), cyclin-dependent
kinase5,mitogen-activatedproteinkinase(MAPK),calcium-
calmodulin kinase, and protein kinase C [119]. It has been
suggested that the accumulation of Abeta may appear before
the tau pathology and that Abeta aggregates may be one of
a cascade of molecular events leading to tau hyperphospho-
rayltion [120–122]. On the other hand, it was reported that
overexpression of tau inhibited kinesin-dependent transport
of peroxisomes, neurofilaments, and Golgi-derived vesicles
into neurites, causing transport defects in primary neuronal
cells including the trafficking of APP [123]. In particular,
the transport of APP into axons and dendrites was blocked,
causing its accumulation in the cell body [123].
Although less well studied, evidence has shown that
oxidative stress is interlinked with tau pathology. It was also
shownthatthecellsoverexpressingtauproteinhadincreased
susceptibility against oxidative stress, perhaps due to the
depletion of peroxisomes [123]. In a drosophila model of
human tauopathies expressing a disease-related mutant form
of human tau (tau R406W), reduction of gene dosage of
thioredoxin reductase (TrxR) or mitochondrial SOD2
enhancedtau-inducedneurodegenerativehistologicalabnor-
malities and neuronal apoptosis [124]. In contrast, over-
expression of these antioxidant enzymes or treatment with
vitamin E attenuated tau-induced neuronal cell death [124].
Moreover, in cortical neurons derived from a transgenic rat
model expressing a human truncated variant form of tau
protein,itwasobservedthatthelevelsofROSwereincreased
when compared to control nontransgenic neurons, while
antioxidants such as vitamin C significantly eliminated the
elevation of ROS [125, 126]. These observations suggest that
tau-induced neurotoxicity is at least partially mediated by
oxidative damage [124]. The linkage between oxidative
stress and tau pathology was further demonstrated in P301S
and P301L transgenic mouse models carrying the human
tau gene with P301S or P301L mutations, which exhibit
an accumulation of hyperphosphorylated tau and develop
neurofibrillary tangles and neurodegeneration [127]. Mito-
chondrial dysfunction together with reduced NADH-ubi-
quinone oxidoreductase activity was found in P301L tau
transgenic mice, which was associated with increased ROS
production, impaired mitochondrial respiration and ATP
synthesis in aged animals [128]. Similarly, the brains of
P301S transgenic mice exhibited signs of elevated oxidative
stress including increased protein carbonyl levels in cortex
mitochondria, alterations in the activity and content of
mitochondrial enzymes involved in ROS formation and
energy metabolism, suggesting that oxidative stress and
mitochondrial dysfunction might play an important role in
tau pathology [129]. Consistently, administration of P301S
mice with coenzyme Q10, an antioxidant and a key com-
ponent of the electron transport chain, significantly in-
creased complex I activity and reduced lipid peroxidation
while improving survival and behavioral deficits of the mice6 Oxidative Medicine and Cellular Longevity
[130]. Furthermore, the convergence of Abeta and tau
pathologies on mitochondria dysfunction was demonstrated
inatripletransgenicmousemodel[pR5/APP/PS2](
tripleAD),
which exhibits both Abeta and tau pathologic features of the
disease in the brain of the animal [131]. Proteomics analyses
of the
tripleAD brain samples demonstrated a massive dereg-
ulationof24proteins,ofwhichonethirdweremitochondrial
proteinsmainlyrelatedtocomplexesIandIVoftheoxidative
phosphorylation system [132]. Notably, deregulation of
mitochondrialcomplexIVwasshowntobeAbetadependent,
while deregulation of complex I was tau dependent [132].
The effects of Abeta and tau on mitochondrial function were
found to be synergistic and age associated, resulting in the
decrease of the mitochondrial respiratory capacity and the
reduction of ATP synthesis, which finally led to the synaptic
loss, and neuronal death [132].
Growing evidence has also shown that oxidative stress
may have a role in the hyperphosphoryaltion and polymer-
ization of tau. The oxidation of fatty acids, which is found
to be elevated in AD brains, was reported to facilitate the
polymerization of tau, and thus might serve as a possible link
between oxidative stress and the formation of the fibrillar
pathology in AD [133]. In Tg2576 AD transgenic mice, de-
ficiency in mitochondrial SOD2 [134] or reduction of cyto-
plasmic SOD1 induced tau phosphorylation, suggesting that
ROS may play a critical role in the hyperphosphoryaltion of
tau [45]. p38 MAPK, which can be activated by oxidative
stress, is capable of phosphorylating tau protein in vitro [135].
In hippocampal and cortical brain regions of AD patients,
activatedp38isfoundexclusivelylocalizedtoNFTandcoim-
munoprecipitated with PHF-tau, suggesting that it might be
involvedinthephosphorylationoftauinvivo[136].Thus,p38
maybeacandidatethatlinksthephosphorylationoftauwith
increased oxidative stress in AD.
6. Conclusions
In summary, evidence has demonstrated that oxidative stress
is inextricably linked with several major pathological pro-
cesses in AD including Abeta-induced neurotoxicity, tau
pathology, mitochondria dysfunction, and metal dyshome-
ostasis. Excessive ROS may be generated from mitochon-
dria dysfunction and/or aberrant accumulation of transition
metals, perhaps caused by a combination of abnormal Abeta
accumulation and tau pathology, eventually resulting in
oxidative stress. Oxidative stress, which mediates the neu-
rotoxicity induced by abnormal accumulation of Abeta and
tauproteins,mayaugmentAbetaproductionandaggregation
as well as facilitate tau phosphorylation and polymerization,
further enhancing a variety of neurotoxic events including
ROS production, thus forming a vicious cycle that promotes
the initiation and progression of AD. Regardless a primary
or secondary event, oxidative stress is an important factor
contributing to the development of AD. Removal of ROS or
prevention of their formation may delay the onset or slow
down the progression of AD through multiple mechanisms
including, but not limited to, reduction of oxidative stress-
mediated neuronal toxicity, inhibition of Abeta production
and aggregation, decrease of tau phosphorylation and poly-
merization, and restoration of mitochondria function and
metal homeostasis. Therefore, AD prevention or treatment
withnaturalantioxidantmaybeanapproachthatiscapableof
targeting a number of different molecular events implicated
in the pathogenesis of AD.
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